Ladenburg Starts Coverage On Flex Pharma (FLKS) with $12.0 Target; Opaleye Management Boosted By $900,000 Its Momenta Pharmaceuticals (MNTA) Holding

Among 5 analysts covering Flex Pharma (NASDAQ:FLKS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Flex Pharma has $4000 highest and $1000 lowest target. $19’s average target is 335.78% above currents $4.36 stock price. Flex Pharma had 7 analyst reports since August 21, 2015 according to SRatingsIntel. The company was upgraded on Wednesday, September 2 by Zacks. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, August 3 report. The stock has “Hold” rating by Zacks on Friday, August 21. The firm earned “Buy” rating on Thursday, September 7 by Roth Capital. Cantor Fitzgerald maintained the shares of FLKS in report on Tuesday, July 25 with “Hold” rating. Cantor Fitzgerald downgraded Flex Pharma, Inc. (NASDAQ:FLKS) on Friday, October 14 to “Hold” rating.

Opaleye Management Inc increased Momenta Pharmaceuticals Inc (MNTA) stake by 11.11% reported in 2017Q3 SEC filing. Opaleye Management Inc acquired 50,000 shares as Momenta Pharmaceuticals Inc (MNTA)’s stock declined 18.16%. The Opaleye Management Inc holds 500,000 shares with $9.25M value, up from 450,000 last quarter. Momenta Pharmaceuticals Inc now has $1.26 billion valuation. It closed at $16.45 lastly. It is down 54.42% since January 28, 2017 and is uptrending. It has outperformed by 37.72% the S&P500.

Investors sentiment decreased to 1.73 in Q3 2017. Its down 0.25, from 1.98 in 2017Q2. It dropped, as 16 investors sold MNTA shares while 29 reduced holdings. 16 funds opened positions while 62 raised stakes. 70.23 million shares or 2.61% more from 68.45 million shares in 2017Q2 were reported. Royal Commercial Bank Of Canada owns 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 35,172 shares. Armistice Ltd owns 0.29% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 132,000 shares. Pictet Asset Mgmt Ltd has invested 0.01% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Guggenheim Limited Liability Corporation invested in 45,659 shares or 0% of the stock. State Of Tennessee Treasury Department stated it has 66,596 shares. Dimensional Fund Advisors Limited Partnership reported 704,031 shares stake. Amica Pension Fund Board Of Trustees reported 72,382 shares stake. Raymond James Associate stated it has 15,971 shares or 0% of all its holdings. Invesco Ltd accumulated 3.51 million shares or 0.02% of the stock. Whittier Communication accumulated 100,428 shares or 0.07% of the stock. Renaissance Tech Llc holds 0.03% or 1.45M shares in its portfolio. Primecap Mgmt Comm Ca owns 2.84 million shares or 0.04% of their US portfolio. Wells Fargo & Com Mn holds 219,520 shares. Credit Suisse Ag holds 0% or 110,596 shares in its portfolio. Pennsylvania-based Nationwide Fund Advsr has invested 0.01% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Among 12 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. Momenta Pharmaceuticals had 27 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 3 by Maxim Group. The rating was downgraded by Leerink Swann on Wednesday, February 22 to “Mkt Perform”. The rating was maintained by Leerink Swann on Tuesday, October 13 with “Outperform”. The company was maintained on Tuesday, October 31 by Cowen & Co. The firm earned “Overweight” rating on Tuesday, October 11 by Barclays Capital. Aegis Capital initiated the shares of MNTA in report on Tuesday, November 22 with “Hold” rating. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has “Hold” rating given on Thursday, October 5 by Stifel Nicolaus. The stock has “Equal-Weight” rating by Barclays Capital on Monday, November 23. Barclays Capital maintained Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) rating on Tuesday, January 31. Barclays Capital has “Overweight” rating and $20 target. Leerink Swann maintained Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) rating on Wednesday, May 4. Leerink Swann has “Outperform” rating and $18 target.

Since August 2, 2017, it had 0 buys, and 10 insider sales for $1.49 million activity. Kaundinya Ganesh Venkataraman sold $6,424 worth of stock or 387 shares. On Monday, August 21 the insider WHEELER CRAIG A sold $62,008. 5,500 shares were sold by Stoner Elizabeth, worth $72,050 on Wednesday, December 13. Another trade for 802 shares valued at $12,190 was sold by Leicher Bruce.

The stock decreased 0.68% or $0.03 during the last trading session, reaching $4.36. About 72,384 shares traded or 38.80% up from the average. Flex Pharma, Inc. (NASDAQ:FLKS) has declined 70.24% since January 28, 2017 and is downtrending. It has underperformed by 86.94% the S&P500.

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company has market cap of $78.36 million. The firm operates through two divisions, Consumer Operations and Drug Development. It currently has negative earnings. The Company’s lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis.